Cargando…

Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients

INTRODUCTION: To compare glycemic variability (GV) and time in range (TIR) in Chinese patients with type 2 diabetes (T2D) initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin using continuous glucose monitoring (CGM). METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ling, James, Poon, Emily W. M., Yang, Aimin, Yeung, Theresa, Loo, Kitman, Ozaki, Risa, Ma, Ronald C. W., Luk, Andrea O. Y., Kong, Alice P. S., Chan, Juliana C. N., Chow, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099948/
https://www.ncbi.nlm.nih.gov/pubmed/33738774
http://dx.doi.org/10.1007/s13300-021-01046-6
_version_ 1783688677427249152
author Ling, James
Poon, Emily W. M.
Yang, Aimin
Yeung, Theresa
Loo, Kitman
Ozaki, Risa
Ma, Ronald C. W.
Luk, Andrea O. Y.
Kong, Alice P. S.
Chan, Juliana C. N.
Chow, Elaine
author_facet Ling, James
Poon, Emily W. M.
Yang, Aimin
Yeung, Theresa
Loo, Kitman
Ozaki, Risa
Ma, Ronald C. W.
Luk, Andrea O. Y.
Kong, Alice P. S.
Chan, Juliana C. N.
Chow, Elaine
author_sort Ling, James
collection PubMed
description INTRODUCTION: To compare glycemic variability (GV) and time in range (TIR) in Chinese patients with type 2 diabetes (T2D) initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin using continuous glucose monitoring (CGM). METHODS: This was a 24-week, open-label exploratory study with 1:1 randomization comparing patient-adjusted titration of Gla-300 (n = 23) versus NPH (n = 23) at bedtime in insulin-naïve T2D patients on maximum oral glucose-lowering drugs. The starting dose was 0.2 U/kg/day and with self-titration of one unit per week to achieve a target fasting glucose of 4.4–6 mmol/l, without hypoglycemia. Participants had masked CGM at baseline, weeks 11 and 24. The primary outcome was between-treatment differences in CGM glucose standard deviation (SD) at week 24. RESULTS: HbA1c at week 24 were similar, with 21% of Gla-300 versus 4% of NPH-treated patients achieving HbA1c < 7% without confirmed hypoglycemia. There were no differences in anytime glucose SD at week 24 (LS mean difference − 0.08 mmol/l, 95% CI [− 0.42–0.26], p = 0.63). Anytime %TIRs (3.9–10.0 mmol/l) at week 24 were similar (p = 0.91). Nocturnal % time below range < 3.9 mmol/l was significantly lower in the Gla-300 group (least squares (LS) mean difference – 5.03% [− 9.92 to − 0.14], p = 0.04) with lower % coefficient of variation (LS mean difference − 4.5% [− 8.1 to − 0.8], p = 0.018). Diurnal TIR was higher in Gla-300 patients at week 11 but there were no differences at week 24. CONCLUSIONS: Once-daily bedtime Gla-300 was associated with lower nocturnal GV, time below range and self-reported hypoglycemia in insulin-naïve Chinese T2D patients over a 24-week study period, as compared with NPH insulin. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03389490. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01046-6.
format Online
Article
Text
id pubmed-8099948
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-80999482021-05-11 Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients Ling, James Poon, Emily W. M. Yang, Aimin Yeung, Theresa Loo, Kitman Ozaki, Risa Ma, Ronald C. W. Luk, Andrea O. Y. Kong, Alice P. S. Chan, Juliana C. N. Chow, Elaine Diabetes Ther Original Research INTRODUCTION: To compare glycemic variability (GV) and time in range (TIR) in Chinese patients with type 2 diabetes (T2D) initiated on once-daily bedtime insulin glargine 300U/ml (Gla-300) versus neutral protamine Hagedorn (NPH) insulin using continuous glucose monitoring (CGM). METHODS: This was a 24-week, open-label exploratory study with 1:1 randomization comparing patient-adjusted titration of Gla-300 (n = 23) versus NPH (n = 23) at bedtime in insulin-naïve T2D patients on maximum oral glucose-lowering drugs. The starting dose was 0.2 U/kg/day and with self-titration of one unit per week to achieve a target fasting glucose of 4.4–6 mmol/l, without hypoglycemia. Participants had masked CGM at baseline, weeks 11 and 24. The primary outcome was between-treatment differences in CGM glucose standard deviation (SD) at week 24. RESULTS: HbA1c at week 24 were similar, with 21% of Gla-300 versus 4% of NPH-treated patients achieving HbA1c < 7% without confirmed hypoglycemia. There were no differences in anytime glucose SD at week 24 (LS mean difference − 0.08 mmol/l, 95% CI [− 0.42–0.26], p = 0.63). Anytime %TIRs (3.9–10.0 mmol/l) at week 24 were similar (p = 0.91). Nocturnal % time below range < 3.9 mmol/l was significantly lower in the Gla-300 group (least squares (LS) mean difference – 5.03% [− 9.92 to − 0.14], p = 0.04) with lower % coefficient of variation (LS mean difference − 4.5% [− 8.1 to − 0.8], p = 0.018). Diurnal TIR was higher in Gla-300 patients at week 11 but there were no differences at week 24. CONCLUSIONS: Once-daily bedtime Gla-300 was associated with lower nocturnal GV, time below range and self-reported hypoglycemia in insulin-naïve Chinese T2D patients over a 24-week study period, as compared with NPH insulin. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03389490. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-021-01046-6. Springer Healthcare 2021-03-18 2021-05 /pmc/articles/PMC8099948/ /pubmed/33738774 http://dx.doi.org/10.1007/s13300-021-01046-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Ling, James
Poon, Emily W. M.
Yang, Aimin
Yeung, Theresa
Loo, Kitman
Ozaki, Risa
Ma, Ronald C. W.
Luk, Andrea O. Y.
Kong, Alice P. S.
Chan, Juliana C. N.
Chow, Elaine
Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title_full Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title_fullStr Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title_full_unstemmed Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title_short Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naïve Chinese Type 2 Diabetes Patients
title_sort glycemic variability and time in range during self-titration of once daily insulin glargine 300 u/ml versus neutral protamine hagedorn insulin in insulin-naïve chinese type 2 diabetes patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099948/
https://www.ncbi.nlm.nih.gov/pubmed/33738774
http://dx.doi.org/10.1007/s13300-021-01046-6
work_keys_str_mv AT lingjames glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT poonemilywm glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT yangaimin glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT yeungtheresa glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT lookitman glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT ozakirisa glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT maronaldcw glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT lukandreaoy glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT kongaliceps glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT chanjulianacn glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients
AT chowelaine glycemicvariabilityandtimeinrangeduringselftitrationofoncedailyinsulinglargine300umlversusneutralprotaminehagedorninsulinininsulinnaivechinesetype2diabetespatients